By Evan Lewis, PhD
Toenail fungus affects between 10 and 15 percent of the population. Most people who have it have had it for years before seeking treatment. When they do seek treatment, they face a range of options — from expensive prescription topicals to over-the-counter natural alternatives — with genuinely different tradeoff profiles.
This article compares two of the most evidence-backed options side by side: Jublia (efinaconazole 10%), the prescription topical antifungal that represents the current pharmaceutical standard for topical treatment, and IodinePure's aqueous iodine formulation, which is supported by three published clinical studies and brings a fundamentally different approach to the same problem.
The goal here is honest comparison — not to dismiss either option, but to give you the information you need to understand what each does, what the evidence says, and which is right for your situation.
What Is Jublia?
Jublia is the brand name for efinaconazole 10% solution, a prescription topical antifungal approved by both the FDA (United States) and Health Canada for the treatment of onychomycosis — fungal nail infection — caused by the dermatophytes Trichophyton rubrum and Trichophyton mentagrophytes, which are responsible for the majority of toenail fungal infections.
Jublia belongs to the azole class of antifungals — the same class that includes the oral fluconazole and the common antifungal clotrimazole. It is applied as a liquid solution directly to the nail surface, where it is designed to penetrate the nail plate and reach the fungal organisms growing beneath.
How Jublia Works
Efinaconazole inhibits an enzyme called lanosterol 14α-demethylase — a critical enzyme in the fungal ergosterol synthesis pathway. Ergosterol is the primary sterol component of the fungal cell membrane; it performs the same structural role in fungi that cholesterol performs in human cell membranes. Without ergosterol synthesis, fungal cell membranes become structurally compromised, leading to cell death.
This is a highly targeted mechanism — it disrupts a specific biochemical pathway unique to fungi. The advantage of targeted mechanism is precision; the consideration is that targeting a single pathway creates the conditions for resistance to develop, as organisms that develop alternate pathways or mutations in the target enzyme can survive treatment.
Clinical Evidence for Jublia
Jublia's evidence base comes from two pivotal Phase 3 clinical trials that supported its FDA and Health Canada approval. In these randomised, controlled trials with daily application over 48 weeks, efinaconazole 10% achieved:
- Complete cure rates (complete clearance and mycological cure combined) of approximately 15 to 18 percent
- Mycological cure rates (laboratory-confirmed clearance of the fungal organism) of approximately 45 to 55 percent
These numbers require context to be understood properly. Mycological cure — clearing the fungus as confirmed by laboratory culture or microscopy — is the clinically meaningful metric, because complete visual clearance of the nail lags months behind mycological cure due to the pace of nail growth. The 45 to 55 percent mycological cure rate at 52 weeks is meaningfully superior to earlier topical antifungals like ciclopirox and represents the current topical standard.
Cost and Practicalities
Without insurance coverage, Jublia costs approximately $600 to $900 per bottle in Canada. Treatment requires 48 weeks of daily application — nearly a full year. It requires a prescription, which requires a podiatrist or dermatologist visit. For patients with extended health benefits that cover Jublia, cost is substantially reduced or eliminated. For patients without this coverage, the cost is a significant practical barrier.
Who Jublia Is Right For
Jublia is best suited for patients with moderate to severe nail fungus who have not achieved results with OTC approaches, who are not candidates for oral terbinafine (due to liver concerns, drug interactions, or personal preference against systemic medication), and who have insurance coverage that makes the cost manageable. It is an FDA and Health Canada-approved treatment with a substantial clinical trial evidence base — for the right patient in the right situation, it is a well-supported choice.
What Is IodinePure Aqueous Iodine?
IodinePure's EZ Clear Nails is an aqueous iodine solution — elemental iodine stabilised in distilled water — formulated for daily topical application to the nail. It contains two ingredients: iodine and distilled water. It is Health Canada approved for cosmetic use. It does not require a prescription and is available directly.
Aqueous iodine is not a new compound repurposed for nail care. Iodine has been used as an antimicrobial in clinical settings for over 150 years — one of the longest clinical safety records of any topical agent. Its activity against fungi, bacteria, and other microorganisms is well-documented across this history.
How Aqueous Iodine Works
Aqueous iodine works through multiple simultaneous mechanisms, which distinguishes it from the single-enzyme-target approach of azole antifungals. Iodine disrupts fungal cell membranes directly through oxidative damage — iodine reacts with and damages the lipid structures of cell membranes, compromising membrane integrity and cell viability. It also interferes with fungal protein structures, disrupting enzyme activity and cellular function through protein modification.
The multi-mechanism approach is associated with low resistance potential. For iodine to be resisted, an organism would need to develop defences against multiple simultaneous attack vectors — a significantly higher evolutionary bar than developing resistance to a single enzyme inhibitor. In over 150 years of clinical iodine use, significant resistance development has not been observed.
Clinical Evidence for Aqueous Iodine
Three published studies provide the evidence base for aqueous iodine in fungal nail infections:
PMC1569938 — published in the Journal of Family Practice, this study examined decolorized aqueous iodine applied daily to toenails affected by onychomycosis. Patients in the treatment group demonstrated significant clinical improvement compared to controls, establishing daily aqueous iodine application as a clinically supported protocol for fungal nail infection. This remains the primary clinical reference for this treatment approach.
PMC4599634 — this study examined iodine-based formulations for onychomycosis, specifically examining povidone-iodine combined with DMSO (a penetration enhancer) for nail fungus treatment. The study demonstrated clinical improvement in the treatment group, contributing to understanding of how iodine-based formulations can be delivered effectively beneath the nail plate.
JAAD S0190-9622(14)00459-9 — published in the Journal of the American Academy of Dermatology, this study examined a topical iodine nail solution and confirmed in vitro activity against dermatophyte fungi — specifically the organisms most commonly responsible for onychomycosis. This extends the evidence beyond clinical outcome studies to mechanistic confirmation against the target pathogens.
Together, these three studies represent a meaningful evidence base — not the scale of pharmaceutical registration trials, but legitimate peer-reviewed evidence for a non-prescription option. The comparison with Jublia's trial programme is a comparison of a pharmaceutical regulatory approval process against academic research literature, which is an inherent difference in the type of evidence rather than simply the quality.
Who IodinePure Is Right For
Aqueous iodine is best suited for patients with mild to moderate nail fungus as a first-line daily treatment; patients who prefer a natural, non-prescription approach; patients without insurance coverage for Jublia for whom the cost barrier is significant; and as a preventive and maintenance protocol following a course of prescription treatment. It is also a reasonable choice for anyone who wants to begin a consistent daily protocol while they decide on a longer-term treatment approach.
Head-to-Head Comparison
| Feature | Jublia (Efinaconazole 10%) | IodinePure EZ Clear Nails |
|---|---|---|
| Mechanism | Inhibits lanosterol 14α-demethylase (single enzyme target); disrupts ergosterol synthesis | Multi-mechanism oxidative disruption of fungal cell membranes and protein structures |
| Clinical Evidence | Phase 3 RCTs (FDA/Health Canada registration trials); high-quality pharmaceutical-level evidence | Three published peer-reviewed studies (PMC1569938, PMC4599634, JAAD S0190-9622(14)00459-9) |
| Mycological Cure Rate | 45–55% at 52 weeks (clinical trial conditions) | Not directly comparable; clinical studies show significant improvement |
| Cost (Canada) | $600–$900 per bottle without insurance | Significantly more affordable; fraction of prescription cost |
| Prescription Required | Yes — requires podiatrist or dermatologist visit | No — available directly without prescription |
| Staining | No staining | No staining (non-staining aqueous formulation) |
| Ease of Daily Use | Applicator brush; daily application to nail; drying time required | Spray or brush application; fast-absorbing solution; two-ingredient formula |
| Resistance Potential | Azole resistance documented in clinical literature for class | Very low; multi-mechanism activity; no observed resistance in 150+ years of use |
| Health Canada Approved | Yes — approved as prescription drug (DIN) | Yes — approved for cosmetic use |
| Ingredient Count | Multiple (active + polymer carrier, penetration enhancers, preservatives) | Two (iodine and distilled water) |
The Compliance Factor
The comparison table above captures a lot, but it does not capture the variable that often matters most in real-world nail fungus treatment: daily compliance over months.
Both Jublia and aqueous iodine require sustained daily application. Jublia requires 48 weeks — nearly a full year. Aqueous iodine protocols are recommended for a minimum of 90 days. Both options are working toward the same underlying goal: consistent topical exposure to the nail and nail unit, day after day, for long enough that the infected nail tissue grows out and is replaced by healthy nail.
The nail grows at approximately 3 mm per month. A toenail that is substantially infected may require 9 to 12 months of growth to fully clear visually — regardless of how effective the treatment is at clearing the fungal organism. There is no shortcut around the pace of nail biology.
What this means practically is that compliance is not a secondary consideration — it is often the primary variable separating patients who achieve clearance from those who do not. A treatment that a patient will consistently apply every day for 90 to 180 days will, in the real world, outperform a clinically superior treatment that a patient abandons at week 8 because the cost was prohibitive, the routine was inconvenient, or the lack of visible progress was discouraging.
This is why cost and accessibility are not just commercial considerations — they are clinical ones. And it is why the simplified two-ingredient formula and no-prescription-required accessibility of aqueous iodine are meaningful factors in the patient's realistic compliance picture.
What I Recommend
For mild to moderate toenail fungus in patients approaching treatment for the first time, I consider aqueous iodine a clinically rational starting point. Three published studies support it, the mechanism is well-understood, the cost and accessibility profile makes consistent daily use achievable, and the 150-year safety record is as well-documented as any topical compound used in medicine.
For moderate to severe infections, for infections that have not responded to a consistent OTC protocol, or for patients who want the highest-documented-efficacy topical option, a conversation with a podiatrist about prescription options — including Jublia and oral terbinafine — is the appropriate next step. These are not competing recommendations: many patients use aqueous iodine as a daily maintenance and preventive protocol alongside or following prescription treatment.
The honest position is that Jublia has stronger clinical trial evidence by virtue of the pharmaceutical registration trial process, and oral terbinafine has higher documented cure rates than either topical option. Aqueous iodine has a genuine evidence base, meaningful practical advantages, and a different set of tradeoffs. These options complement each other more than they compete — the right choice depends on severity, patient circumstances, insurance coverage, and personal preference about natural versus prescription approaches.
Already Using Jublia? Here's How to Add IodinePure
If you are on a Jublia course and want to add an iodine routine, timing matters — iodine can break down the efinaconazole film if the two are applied together. Our guide on how to use IodinePure alongside Jublia walks through the simple morning-and-night schedule that keeps them from working against each other. If you are considering clinic light therapy instead, see how to fit IodinePure around Toe FX treatments, and for the full landscape of choices, our 2026 guide to toenail fungus treatments in Canada.
Frequently Asked Questions
Is there an alternative to Jublia?
Yes. The prescription alternatives to Jublia for toenail fungus include oral terbinafine (Lamisil) — the highest-efficacy option for moderate to severe infections — and ciclopirox (Penlac), an older prescription topical lacquer. Non-prescription alternatives with published clinical evidence include aqueous iodine formulations. For patients for whom cost is a significant factor, the combination of aqueous iodine daily protocol and a podiatrist discussion about oral options is a reasonable alternative pathway.
Is IodinePure as effective as Jublia?
This question cannot be answered with a direct comparison, because the two products have not been directly compared in a head-to-head clinical trial. Jublia has Phase 3 registration trial data showing 45 to 55 percent mycological cure at 52 weeks. Aqueous iodine has three published studies demonstrating significant clinical improvement in fungal nail infections. What can be said honestly is that both have clinical evidence, they work through different mechanisms, and their practical tradeoffs — cost, accessibility, ingredient profile, resistance potential — differ in ways that are relevant to different patients. For mild to moderate infections, aqueous iodine is a supported starting point. For more severe cases, Jublia or oral options have stronger documented efficacy.
Can I use iodine instead of Jublia?
For mild to moderate infections and as a first-line approach before prescription treatment, yes — aqueous iodine has published evidence supporting its use for onychomycosis and is a reasonable starting protocol. If you have moderate to severe nail fungus, multiple nails involved, or you have already tried a consistent OTC protocol without response, discussing prescription options with a podiatrist or dermatologist is the more appropriate step. The two options are not mutually exclusive — some patients use aqueous iodine as a daily maintenance protocol alongside or following prescription treatment.
How does aqueous iodine compare to prescription antifungals?
Aqueous iodine differs from prescription antifungals in mechanism (multi-pathway oxidative disruption versus targeted enzyme inhibition), evidence level (published academic studies versus pharmaceutical registration trials), cost (significantly more affordable), and accessibility (no prescription required). The tradeoff is that prescription options — particularly oral terbinafine — have higher documented cure rates in controlled trial conditions for moderate to severe infections. For mild infections and patients seeking a natural, accessible, non-prescription option, aqueous iodine is a clinically supported choice. The selection between natural and prescription options should account for infection severity, patient circumstances, and individual preferences.
What is the most affordable nail fungus treatment that actually works?
Aqueous iodine formulations — including IodinePure EZ Clear Nails — represent the most affordable option with published clinical evidence. No prescription is required, cost is a fraction of Jublia, and three studies support the approach. For patients for whom cost is a significant factor, this is a clinically grounded starting point that avoids the $600 to $900 per-bottle cost of Jublia without insurance. Oral terbinafine, when appropriate and covered by a provincial formulary or benefits plan, is also relatively affordable — the cost varies but is typically much lower than Jublia. Discuss coverage with your pharmacy and benefits provider.
Start the 90-Day Protocol
IodinePure EZ Clear Nails delivers stabilised aqueous iodine to the nail in a non-staining, two-ingredient formula backed by three published studies. No prescription required. Affordable enough that daily use for 90 days is actually achievable.
